# Wiseheart Medval

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wiseheart-medval

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.wiseheartmed.com
- Latest round: Series A (Jan 7, 2026)
- Investors on record: 3

## About

Based in Beijing, China and founded in 2021, Beijing Huixin Wiseheart Medval Biotechnology Co., Ltd, trading under the name Wiseheart Medval, operates as a biopharmaceutical company, focusing on cell therapy for neurological diseases. The company built a GMP-grade cell product manufacturing plant in Beijing's Zhongguancun Life Science Park. It has cooperated with Xuanwu Hospital. In January 2026, Wiseheart Medval raised over CNY 100 million in series A funding from new lead investor Beijing Jingneng Tongxin Investment Management, returning investor BCT Capital and new investor Fuzhi Investment.

The company uses reprogramming technology and non-integrating systems to obtain neural stem cells (iNSC) directly induced from human peripheral blood single nucleated cells or fibroblasts, and simultaneously and directionally differentiate them into dopaminergic neural precursor cells (iNSC-DAP). Its core products, Dopaminergic Neural Precursor Cells (iNSC-DAP) Injection, can treat Parkinson's disease with clinical intervention through stereotactic transplantation clinical technology. This technology allows for autologous or allogeneic cell therapy, avoiding the ethical issues involved in embryonic stem cell harvesting.

The company’s revenue is generated by the research, development, and commercialization of cell therapy drugs and regenerative medicine technologies.

The company plans to use the series A funding to advance the clinical research of cell therapy products for nervous system diseases and accelerate the transformation of innovative results into clinical and industrial applications.

## Funding rounds

- Series A, Jan 7, 2026 — BCT Capital, Beijing Jingneng Tongxin Investment Management
- Angel, Jun 10, 2022 — Green Pine Capital Partners

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Angel
- BCT Capital (https://capitalatlas.ai/funds/bct-capital) — Series A
- Beijing Jingneng Tongxin Investment Management (https://capitalatlas.ai/funds/beijing-jingneng-tongxin-investment-management) — Series A